{
  "success": true,
  "pagesUsed": [
    4,
    12,
    19
  ],
  "modelUsed": "gemini-3-flash-preview",
  "narrative": {
    "narrativeContents": [
      {
        "id": "nc_1",
        "name": "PROTOCOL SYNOPSIS",
        "text": "PROTOCOL SYNOPSIS",
        "order": 0,
        "instanceType": "NarrativeContent",
        "sectionTitle": "PROTOCOL SYNOPSIS",
        "sectionType": {
          "id": "338f03be-15cd-41b4-bb51-467035a742c0",
          "code": "Synopsis",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Synopsis",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_2",
        "name": "BACKGROUND",
        "text": "BACKGROUND",
        "order": 1,
        "instanceType": "NarrativeContent",
        "sectionNumber": "1",
        "sectionTitle": "BACKGROUND",
        "sectionType": {
          "id": "55f915fe-d45f-4457-a2b7-42b3f5391036",
          "code": "Introduction",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Introduction",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_2_1",
          "nci_2_2",
          "nci_2_3",
          "nci_2_4",
          "nci_2_5",
          "nci_2_6",
          "nci_2_7",
          "nci_2_8",
          "nci_2_9",
          "nci_2_10",
          "nci_2_11",
          "nci_2_12",
          "nci_2_13",
          "nci_2_14",
          "nci_2_15",
          "nci_2_16"
        ]
      },
      {
        "id": "nc_3",
        "name": "OBJECTIVES AND ENDPOINTS",
        "text": "OBJECTIVES AND ENDPOINTS",
        "order": 2,
        "instanceType": "NarrativeContent",
        "sectionNumber": "2",
        "sectionTitle": "OBJECTIVES AND ENDPOINTS",
        "sectionType": {
          "id": "1eff583c-751a-490a-b508-f3ac8823c8e0",
          "code": "Objectives",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Objectives",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_4",
        "name": "STUDY DESIGN",
        "text": "STUDY DESIGN",
        "order": 3,
        "instanceType": "NarrativeContent",
        "sectionNumber": "3",
        "sectionTitle": "STUDY DESIGN",
        "sectionType": {
          "id": "6123a3e1-c75e-4235-aa70-d4e8a0c707ff",
          "code": "Study Design",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Study Design",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_4_1",
          "nci_4_2",
          "nci_4_3",
          "nci_4_4"
        ]
      },
      {
        "id": "nc_5",
        "name": "Schedule of Activities",
        "text": "Schedule of Activities",
        "order": 4,
        "instanceType": "NarrativeContent",
        "sectionNumber": "Appendix 1",
        "sectionTitle": "Schedule of Activities",
        "sectionType": {
          "id": "bc3fcb38-b56a-4d7f-bef7-ef430c89295b",
          "code": "Appendix",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Appendix",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_6",
        "name": "Anti-Drug Antibody, Pharmacokinetic, Pharmacodynamic, and Exploratory Biomarker Sampling Schedule",
        "text": "Anti-Drug Antibody, Pharmacokinetic, Pharmacodynamic, and Exploratory Biomarker Sampling Schedule",
        "order": 5,
        "instanceType": "NarrativeContent",
        "sectionNumber": "Appendix 2",
        "sectionTitle": "Anti-Drug Antibody, Pharmacokinetic, Pharmacodynamic, and Exploratory Biomarker Sampling Schedule",
        "sectionType": {
          "id": "05b7bc5c-f222-456d-8f4b-4dcbfd4a77f8",
          "code": "Appendix",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Appendix",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_7",
        "name": "Response Evaluation Criteria in Solid Tumors: Modified Excerpt from Original Publication",
        "text": "Response Evaluation Criteria in Solid Tumors: Modified Excerpt from Original Publication",
        "order": 6,
        "instanceType": "NarrativeContent",
        "sectionNumber": "Appendix 3",
        "sectionTitle": "Response Evaluation Criteria in Solid Tumors: Modified Excerpt from Original Publication",
        "sectionType": {
          "id": "4a6efed1-d1dd-45e1-bc4e-036aac58b0eb",
          "code": "Appendix",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Appendix",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_8",
        "name": "Patient-Reported Outcome Instruments",
        "text": "Patient-Reported Outcome Instruments",
        "order": 7,
        "instanceType": "NarrativeContent",
        "sectionNumber": "Appendix 4",
        "sectionTitle": "Patient-Reported Outcome Instruments",
        "sectionType": {
          "id": "4e137e5d-bf06-4403-9acf-7b89bb1dfade",
          "code": "Appendix",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Appendix",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_9",
        "name": "Preexisting Autoimmune Diseases",
        "text": "Preexisting Autoimmune Diseases",
        "order": 8,
        "instanceType": "NarrativeContent",
        "sectionNumber": "Appendix 5",
        "sectionTitle": "Preexisting Autoimmune Diseases",
        "sectionType": {
          "id": "333d4a58-a926-4965-bddd-7a52f871f09f",
          "code": "Appendix",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Appendix",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_10",
        "name": "Anaphylaxis Precautions",
        "text": "Anaphylaxis Precautions",
        "order": 9,
        "instanceType": "NarrativeContent",
        "sectionNumber": "Appendix 6",
        "sectionTitle": "Anaphylaxis Precautions",
        "sectionType": {
          "id": "cdaec943-edfb-436e-acd7-5923f3e65e20",
          "code": "Appendix",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Appendix",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_11",
        "name": "Eastern Cooperative Oncology Group (ECOG) Performance Status Scale",
        "text": "Eastern Cooperative Oncology Group (ECOG) Performance Status Scale",
        "order": 10,
        "instanceType": "NarrativeContent",
        "sectionNumber": "Appendix 7",
        "sectionTitle": "Eastern Cooperative Oncology Group (ECOG) Performance Status Scale",
        "sectionType": {
          "id": "72ea06ef-7e5a-49b7-aef6-2e42d0e94500",
          "code": "Appendix",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Appendix",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_12",
        "name": "Cockcroft-Gault formula",
        "text": "Cockcroft-Gault formula",
        "order": 11,
        "instanceType": "NarrativeContent",
        "sectionNumber": "Appendix 8",
        "sectionTitle": "Cockcroft-Gault formula",
        "sectionType": {
          "id": "61823327-6fb6-449f-aec0-3da9aed9bae3",
          "code": "Appendix",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Appendix",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_13",
        "name": "Guide to Interpreting the AE Causality Question",
        "text": "Guide to Interpreting the AE Causality Question",
        "order": 12,
        "instanceType": "NarrativeContent",
        "sectionNumber": "Appendix 9",
        "sectionTitle": "Guide to Interpreting the AE Causality Question",
        "sectionType": {
          "id": "fc42f641-63ee-405a-a591-e016ca6c86d5",
          "code": "Appendix",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Appendix",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_14",
        "name": "Patient Engagement Application",
        "text": "Patient Engagement Application",
        "order": 13,
        "instanceType": "NarrativeContent",
        "sectionNumber": "Appendix 10",
        "sectionTitle": "Patient Engagement Application",
        "sectionType": {
          "id": "f9906911-bf2b-4370-a439-8686ea7b7162",
          "code": "Appendix",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Appendix",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_15",
        "name": "Risks Associated with Atezolizumab and Guidelines for Management of Adverse Events Associated with Atezolizumab",
        "text": "Risks Associated with Atezolizumab and Guidelines for Management of Adverse Events Associated with Atezolizumab",
        "order": 14,
        "instanceType": "NarrativeContent",
        "sectionNumber": "Appendix 11",
        "sectionTitle": "Risks Associated with Atezolizumab and Guidelines for Management of Adverse Events Associated with Atezolizumab",
        "sectionType": {
          "id": "a8d566c6-ceb9-4274-a194-25d5c7099230",
          "code": "Appendix",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Appendix",
          "instanceType": "Code"
        }
      }
    ],
    "narrativeContentItems": [
      {
        "id": "nci_2_1",
        "name": "Background on Breast cancer",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.1",
        "sectionTitle": "Background on Breast cancer"
      },
      {
        "id": "nci_2_2",
        "name": "Triple-Negative Breast Cancer (TNBC)",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.1.1",
        "sectionTitle": "Triple-Negative Breast Cancer (TNBC)"
      },
      {
        "id": "nci_2_3",
        "name": "Treatment of Metastatic Breast Cancer",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.1.2",
        "sectionTitle": "Treatment of Metastatic Breast Cancer"
      },
      {
        "id": "nci_2_4",
        "name": "Taxanes and Paclitaxel in Metastatic Breast Cancer",
        "text": "",
        "order": 3,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.1.2.1",
        "sectionTitle": "Taxanes and Paclitaxel in Metastatic Breast Cancer"
      },
      {
        "id": "nci_2_5",
        "name": "PD-L1 Inhibitors in the Treatment of TNBC",
        "text": "",
        "order": 4,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.1.2.2",
        "sectionTitle": "PD-L1 Inhibitors in the Treatment of TNBC"
      },
      {
        "id": "nci_2_6",
        "name": "Background on Atezolizumab",
        "text": "",
        "order": 5,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.2",
        "sectionTitle": "Background on Atezolizumab"
      },
      {
        "id": "nci_2_7",
        "name": "Summary of Nonclinical Studies",
        "text": "",
        "order": 6,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.2.1",
        "sectionTitle": "Summary of Nonclinical Studies"
      },
      {
        "id": "nci_2_8",
        "name": "Summary of Clinical Studies in Patients with TNBC",
        "text": "",
        "order": 7,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.2.2",
        "sectionTitle": "Summary of Clinical Studies in Patients with TNBC"
      },
      {
        "id": "nci_2_9",
        "name": "Efficacy of Atezolizumab Monotherapy in Patients with TNBC",
        "text": "",
        "order": 8,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.2.2.1",
        "sectionTitle": "Efficacy of Atezolizumab Monotherapy in Patients with TNBC"
      },
      {
        "id": "nci_2_10",
        "name": "Safety of Atezolizumab Monotherapy",
        "text": "",
        "order": 9,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.2.2.2",
        "sectionTitle": "Safety of Atezolizumab Monotherapy"
      },
      {
        "id": "nci_2_11",
        "name": "Efficacy of Atezolizumab Combined with Chemotherapy in Patients with TNBC",
        "text": "",
        "order": 10,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.2.2.3",
        "sectionTitle": "Efficacy of Atezolizumab Combined with Chemotherapy in Patients with TNBC"
      },
      {
        "id": "nci_2_12",
        "name": "Safety of Atezolizumab Combined with Chemotherapy",
        "text": "",
        "order": 11,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.2.2.4",
        "sectionTitle": "Safety of Atezolizumab Combined with Chemotherapy"
      },
      {
        "id": "nci_2_13",
        "name": "Clinical Pharmacokinetics and Immunogenicity of Atezolizumab",
        "text": "",
        "order": 12,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.2.2.5",
        "sectionTitle": "Clinical Pharmacokinetics and Immunogenicity of Atezolizumab"
      },
      {
        "id": "nci_2_14",
        "name": "Study Rationale and Benefit-Risk Assessment",
        "text": "",
        "order": 13,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.3",
        "sectionTitle": "Study Rationale and Benefit-Risk Assessment"
      },
      {
        "id": "nci_2_15",
        "name": "Atezolizumab",
        "text": "",
        "order": 14,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.3.1",
        "sectionTitle": "Atezolizumab"
      },
      {
        "id": "nci_2_16",
        "name": "Paclitaxel and Combination Treatment with Atezolizumab",
        "text": "",
        "order": 15,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.3.2",
        "sectionTitle": "Paclitaxel and Combination Treatment with Atezolizumab"
      },
      {
        "id": "nci_4_1",
        "name": "Description of the Study",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.1",
        "sectionTitle": "Description of the Study"
      },
      {
        "id": "nci_4_2",
        "name": "Overview of the Study Design",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.1.1",
        "sectionTitle": "Overview of the Study Design"
      },
      {
        "id": "nci_4_3",
        "name": "Independent Data Monitoring Committee",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.1.2",
        "sectionTitle": "Independent Data Monitoring Committee"
      },
      {
        "id": "nci_4_4",
        "name": "End of Study and Length of Study",
        "text": "",
        "order": 3,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.2",
        "sectionTitle": "End of Study and Length of Study"
      }
    ],
    "abbreviations": [
      {
        "id": "abbr_1",
        "abbreviatedText": "TNBC",
        "expandedText": "Triple-Negative Breast Cancer",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_2",
        "abbreviatedText": "PD-L1",
        "expandedText": "Programmed Death-Ligand 1",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_3",
        "abbreviatedText": "ECOG",
        "expandedText": "Eastern Cooperative Oncology Group",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_4",
        "abbreviatedText": "AE",
        "expandedText": "Adverse Event",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_5",
        "abbreviatedText": "CT",
        "expandedText": "computerized tomography",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_6",
        "abbreviatedText": "MRI",
        "expandedText": "magnetic resonance imaging",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_7",
        "abbreviatedText": "PET",
        "expandedText": "Positron Emission Tomography",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_8",
        "abbreviatedText": "CNS",
        "expandedText": "Central Nervous System",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_9",
        "abbreviatedText": "PFS",
        "expandedText": "Progression-Free Survival",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_10",
        "abbreviatedText": "ORR",
        "expandedText": "Objective Response Rate",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_11",
        "abbreviatedText": "DoR",
        "expandedText": "Duration of Response",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_12",
        "abbreviatedText": "CBR",
        "expandedText": "Clinical Benefit Rate",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_13",
        "abbreviatedText": "RECIST",
        "expandedText": "Response Evaluation Criteria in Solid Tumors",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_14",
        "abbreviatedText": "IRC",
        "expandedText": "Independent Review Committee",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_15",
        "abbreviatedText": "PD",
        "expandedText": "Progressive Disease",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_16",
        "abbreviatedText": "EOS",
        "expandedText": "End of Study",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_17",
        "abbreviatedText": "PFS2",
        "expandedText": "Progression-Free Survival 2",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_18",
        "abbreviatedText": "PROs",
        "expandedText": "Patient-Reported Outcomes",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_19",
        "abbreviatedText": "SC",
        "expandedText": "Steering Committee",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_20",
        "abbreviatedText": "iDMC",
        "expandedText": "independent Data Monitoring Committee",
        "instanceType": "Abbreviation"
      }
    ],
    "summary": {
      "sectionCount": 15,
      "itemCount": 20,
      "abbreviationCount": 20
    },
    "studyDefinitionDocument": {
      "id": "sdd_1",
      "name": "A Phase 2, Open-Label Study (IMpassion131)",
      "documentType": "Protocol",
      "language": "en",
      "instanceType": "StudyDefinitionDocument",
      "version": "6.0",
      "contentIds": [
        "nc_1",
        "nc_2",
        "nc_3",
        "nc_4",
        "nc_5",
        "nc_6",
        "nc_7",
        "nc_8",
        "nc_9",
        "nc_10",
        "nc_11",
        "nc_12",
        "nc_13",
        "nc_14",
        "nc_15"
      ]
    }
  },
  "rawResponse": {
    "abbreviations": {
      "abbreviations": [
        {
          "abbreviation": "TNBC",
          "expansion": "Triple-Negative Breast Cancer"
        },
        {
          "abbreviation": "PD-L1",
          "expansion": "Programmed Death-Ligand 1"
        },
        {
          "abbreviation": "ECOG",
          "expansion": "Eastern Cooperative Oncology Group"
        },
        {
          "abbreviation": "AE",
          "expansion": "Adverse Event"
        },
        {
          "abbreviation": "CT",
          "expansion": "computerized tomography"
        },
        {
          "abbreviation": "MRI",
          "expansion": "magnetic resonance imaging"
        },
        {
          "abbreviation": "PET",
          "expansion": "Positron Emission Tomography"
        },
        {
          "abbreviation": "CNS",
          "expansion": "Central Nervous System"
        },
        {
          "abbreviation": "PFS",
          "expansion": "Progression-Free Survival"
        },
        {
          "abbreviation": "ORR",
          "expansion": "Objective Response Rate"
        },
        {
          "abbreviation": "DoR",
          "expansion": "Duration of Response"
        },
        {
          "abbreviation": "CBR",
          "expansion": "Clinical Benefit Rate"
        },
        {
          "abbreviation": "RECIST",
          "expansion": "Response Evaluation Criteria in Solid Tumors"
        },
        {
          "abbreviation": "IRC",
          "expansion": "Independent Review Committee"
        },
        {
          "abbreviation": "PD",
          "expansion": "Progressive Disease"
        },
        {
          "abbreviation": "EOS",
          "expansion": "End of Study"
        },
        {
          "abbreviation": "PFS2",
          "expansion": "Progression-Free Survival 2"
        },
        {
          "abbreviation": "PROs",
          "expansion": "Patient-Reported Outcomes"
        },
        {
          "abbreviation": "SC",
          "expansion": "Steering Committee"
        },
        {
          "abbreviation": "iDMC",
          "expansion": "independent Data Monitoring Committee"
        }
      ]
    },
    "structure": {
      "document": {
        "title": "A Phase 2, Open-Label Study (IMpassion131)",
        "version": "6.0",
        "versionDate": null
      },
      "sections": [
        {
          "number": null,
          "title": "PROTOCOL SYNOPSIS",
          "type": "Synopsis"
        },
        {
          "number": "1",
          "title": "BACKGROUND",
          "type": "Introduction",
          "subsections": [
            {
              "number": "1.1",
              "title": "Background on Breast cancer"
            },
            {
              "number": "1.1.1",
              "title": "Triple-Negative Breast Cancer (TNBC)"
            },
            {
              "number": "1.1.2",
              "title": "Treatment of Metastatic Breast Cancer"
            },
            {
              "number": "1.1.2.1",
              "title": "Taxanes and Paclitaxel in Metastatic Breast Cancer"
            },
            {
              "number": "1.1.2.2",
              "title": "PD-L1 Inhibitors in the Treatment of TNBC"
            },
            {
              "number": "1.2",
              "title": "Background on Atezolizumab"
            },
            {
              "number": "1.2.1",
              "title": "Summary of Nonclinical Studies"
            },
            {
              "number": "1.2.2",
              "title": "Summary of Clinical Studies in Patients with TNBC"
            },
            {
              "number": "1.2.2.1",
              "title": "Efficacy of Atezolizumab Monotherapy in Patients with TNBC"
            },
            {
              "number": "1.2.2.2",
              "title": "Safety of Atezolizumab Monotherapy"
            },
            {
              "number": "1.2.2.3",
              "title": "Efficacy of Atezolizumab Combined with Chemotherapy in Patients with TNBC"
            },
            {
              "number": "1.2.2.4",
              "title": "Safety of Atezolizumab Combined with Chemotherapy"
            },
            {
              "number": "1.2.2.5",
              "title": "Clinical Pharmacokinetics and Immunogenicity of Atezolizumab"
            },
            {
              "number": "1.3",
              "title": "Study Rationale and Benefit-Risk Assessment"
            },
            {
              "number": "1.3.1",
              "title": "Atezolizumab"
            },
            {
              "number": "1.3.2",
              "title": "Paclitaxel and Combination Treatment with Atezolizumab"
            }
          ]
        },
        {
          "number": "2",
          "title": "OBJECTIVES AND ENDPOINTS",
          "type": "Objectives"
        },
        {
          "number": "3",
          "title": "STUDY DESIGN",
          "type": "Study Design",
          "subsections": [
            {
              "number": "3.1",
              "title": "Description of the Study"
            },
            {
              "number": "3.1.1",
              "title": "Overview of the Study Design"
            },
            {
              "number": "3.1.2",
              "title": "Independent Data Monitoring Committee"
            },
            {
              "number": "3.2",
              "title": "End of Study and Length of Study"
            }
          ]
        },
        {
          "number": "Appendix 1",
          "title": "Schedule of Activities",
          "type": "Appendix"
        },
        {
          "number": "Appendix 2",
          "title": "Anti-Drug Antibody, Pharmacokinetic, Pharmacodynamic, and Exploratory Biomarker Sampling Schedule",
          "type": "Appendix"
        },
        {
          "number": "Appendix 3",
          "title": "Response Evaluation Criteria in Solid Tumors: Modified Excerpt from Original Publication",
          "type": "Appendix"
        },
        {
          "number": "Appendix 4",
          "title": "Patient-Reported Outcome Instruments",
          "type": "Appendix"
        },
        {
          "number": "Appendix 5",
          "title": "Preexisting Autoimmune Diseases",
          "type": "Appendix"
        },
        {
          "number": "Appendix 6",
          "title": "Anaphylaxis Precautions",
          "type": "Appendix"
        },
        {
          "number": "Appendix 7",
          "title": "Eastern Cooperative Oncology Group (ECOG) Performance Status Scale",
          "type": "Appendix"
        },
        {
          "number": "Appendix 8",
          "title": "Cockcroft-Gault formula",
          "type": "Appendix"
        },
        {
          "number": "Appendix 9",
          "title": "Guide to Interpreting the AE Causality Question",
          "type": "Appendix"
        },
        {
          "number": "Appendix 10",
          "title": "Patient Engagement Application",
          "type": "Appendix"
        },
        {
          "number": "Appendix 11",
          "title": "Risks Associated with Atezolizumab and Guidelines for Management of Adverse Events Associated with Atezolizumab",
          "type": "Appendix"
        }
      ]
    }
  }
}